Clinical trials: Head and Neck Cancer Metastatic
Head and Neck Cancer, Thromboembolism
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have…
- Trial name
- NCT00020189
- Testing
- acetylsalicylic acid, alvocidib, clopidogrel bisulfate
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Advanced Cancer
Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)
This study aims to study the kinetics of ctDNA levels after the first dose of immune checkpoint inhibitor in patients with recurrent or metastatic head and neck cancer.
- Conditions
- Head and Neck Cancer, Advanced Cancer, Metastatic Cancer, HNSCC
- Trial name
- NCT04606940
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- University Health Network, Toronto
Neoplasms
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
This study is open to adults with advanced cancer (solid tumors) and people with advanced head and neck cancer. The study has 2 parts.
- Trial name
- NCT04958239
- Testing
- BI 765179, Ezabenlimab, Pembrolizumab
- Where
- 48 sites in United States, Australia and 13 more
- Volunteers
- 151 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Cancer
Customized Headrest or Standard Headrest in Holding Patients Still While Undergoing Radiation Therapy for Head and Neck Cancer
RATIONALE: Using a customized headrest to hold patients in one position may help doctors plan treatment for patients with head and neck cancer.
- Trial name
- NCT00973947
- Testing
- questionnaire administration, 3-dimensional conformal radiation therapy, radiation therapy treatment planning/simulation
- Where
- Ireland
- Volunteers
- 40 people
- Sponsor
- Cancer Trials Ireland
Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
This phase II trial compares the effect of adding ipatasertib to pembrolizumab (standard immunotherapy) vs. pembrolizumab alone in treating patients with squamous cell cancer of the head and neck that has come back (recurrent) or…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT05172258
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 20 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer
RATIONALE: Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004163
- Testing
- Trastuzumab
- Where
- 10 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
This study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT05909904
- Testing
- Tislelizumab, BGB-A425, LBL-007
- Where
- 73 sites in United States, Australia and 12 more
- Volunteers
- 160 people
- Sponsor
- BeiGene
Head and Neck Cancer, Carcinoma, Squamous
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
A study of Oxaliplatin and Docetaxel followed by Cetuximab for head and neck cancer patients to determine their effect on the control and reduction of tumor size
- Trial name
- NCT00591149
- Testing
- Oxaliplatin, Docetaxel, Cetuximab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Kansas Medical Center
Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma
Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma
Gemcitabine plus cisplatin (GC) is more effective than fluorouracil plus cisplatin in the treatment of recurrent or metastatic NPC (R/M-NPC). GC is the standard first-line chemotherapy regimen for this population.
- Trial name
- NCT03639467
- Testing
- Anlotinib plus gemcitabine/cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese Academy of Medical Sciences
Locally Advanced or Metastatic Epithelial Tumor
A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors
In phase Ia study, the safety and tolerability of SI-B001 in patients with locally advanced or metastatic epithelial malignancies will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of…
- Trial name
- NCT04603287
- Testing
- SI-B001
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Nasopharyngeal Cancer
To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
The purpose of this study is to assess the efficacy of addition of zometa to anti-neoplastic treatment compared with anti-neoplastic treatment alone, as measured by the primary efficacy variable of SREs (Skeletal Related Events)…
- Trial name
- NCT00697619
- Testing
- Zometa (zoledronic acid)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
The purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies.
- Conditions
- Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Trial name
- NCT06974734
- Testing
- PF-08046037, sasanlimab
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 8 people
- Sponsor
- Pfizer
Head and Neck Squamous Cell Carcinoma
Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China
This trial is main evaluate the efficacy and safety of pembrolizumab combined with chemotherapy in the first-line treatment of Chinese patients with recurrent or metastatic head and neck squamous cell carcinoma
- Trial name
- NCT04857164
- Testing
- Pembrolizumab combined with Chemotherapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Yuankai Shi
Head and Neck Cancer
Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
The purpose of this study is to evaluate the safety and efficacy of the combination of nivolumab plus epacadostat in combination with chemotherapy in first-line recurrent or metastatic patients with squamous cell carcinoma of the…
- Trial name
- NCT03342352
- Testing
- Nivolumab, Epacadostat, Carboplatin
- Sponsor
- Incyte Corporation
Squamous Cell Carcinoma of Head and Neck
Dendritic Cell Vaccine for Head and Neck Cancer
This research study is testing a new treatment of cancer of the head and neck. Purpose This research study is being done to: 1. Test the safety of the experimental cancer vaccine made of dendritic cells.
- Trial name
- Dendritic (NCT00492947)
- Testing
- dendritic cell vaccine
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Esophageal Cancer
Fluorouracil, Irinotecan, Leucovorin, and Cisplatin as First-Line Therapy in Treating Patients With Metastatic Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, irinotecan, leucovorin, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00075738
- Testing
- cisplatin, fluorouracil, irinotecan hydrochloride
- Where
- 15 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Squamous Cell Carcinoma of the Head and Neck Cancer
EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to determine if EMD 1201081 in combination with cetuximab is more efficient than cetuximab alone to control the cancer.
- Trial name
- NCT01040832
- Testing
- Cetuximab, EMD 1201081
- Where
- 35 sites in United States, Belgium and 6 more
- Volunteers
- 107 people
- Sponsor
- EMD Serono
Malignant Neoplasm in the Head and Neck, Metastatic Malignant Neoplasm in the Head and Neck
Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes
This phase I trial tests whether embolization done prior to surgery (preoperative) will improve surgical outcomes in head and neck tumors with large amounts of blood vessels (hypervascular).
- Trial name
- NCT05490381
- Testing
- Iodixanol, Angiogram, Arterial Embolization
- Where
- United States
- Sponsor
- University of Washington
Head and Neck Squamous Cell Carcinoma
Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma
This is a prospective, one-arm exploratory second-line study of carrilizumab combined with bevacizumab plus capecitabine in relapsed metastatic squamous cell carcinoma of the head and neck.
- Trial name
- NCT05965154
- Testing
- Carrilizumab, bevacizumab,capecitabine
- Volunteers
- 22 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma
Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas
Immunotherapy targeting the PD-1/PD-L1 pathway had previously been shown to be efficacious in the treatment of patients with metastatic head and neck squamous cell carcinomas.
- Trial name
- NCT03283605
- Testing
- SBRT, Durvalumab, Tremelimumab
- Where
- 3 sites in Canada
- Volunteers
- 33 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.